Teva and biolojic design announce exclusive license agreement for the development of a therapeutic antibody for atopic dermatitis and asthma

Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd., (nyse and tase:teva) and biolojic design ltd. ("biolojic"), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions, today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of atopic dermatitis and asthma. bd9 is a dual specific antibody that can block both tslp (thymic stroma.
TEVA Ratings Summary
TEVA Quant Ranking